Q1 2026 Phibro Animal Health Corp Earnings Call Transcript
Key Points
- Phibro Animal Health Corp (PAHC) reported a 55% growth in animal health sales and an 85% increase in animal health adjusted EBITDA, indicating strong performance in the first quarter.
- The company successfully integrated the acquired MFA portfolio, leading to an 81% growth in medicated additives.
- Legacy animal health business showed resilience with an 11% overall growth, highlighting strong demand across its diversified portfolio.
- The launch of Restores, a proprietary dental gel for dogs, marks a significant milestone in PAHC's companion animal strategy, potentially driving long-term growth.
- PAHC raised its full-year earnings guidance, reflecting confidence in continued strong performance and strategic investments in future growth.
- Performance products segment experienced a 7% decline in net sales due to lower demand for ingredients used in personal care products.
- Increased SG&A expenses due to higher employee-related costs partially offset the improved gross margin.
- Despite strong Q1 performance, PAHC did not update its revenue guidance, indicating potential caution or conservatism in future projections.
- The company anticipates a slight drop in margins in future quarters due to increased investments in new product launches.
- Corporate expenses increased by $3.4 million, driven by higher employee-related costs, impacting overall profitability.
Hello and thank you for standing by. Welcome to the Phibro Animal Health Corporation first quarter 2026 webcast and conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question, please press 1 on your telephone keypad.
I would now like to turn the conference over to Glenn David, Chief Financial Officer. You may begin.
Thank you, Sarah. Good day and welcome to the Phibro Animal Health Corporation earnings call for our fiscal first quarter ending September 30, 2025. My name is Glenn David, and I am the Chief Financial Officer of Phibro Animal Health Corporation.
I am joined on today's call by Jack Bendheim, Phiibro's Chairman, President and Chief Executive Officer Daniel Bendheim, Director and Executive Vice President of Corporate strategy and Larry Miller, our Chief Operating Officer.
Today we will cover financial performance for our
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
